MyFinsight
Home
Blog
About
Proceeds from the sale of
common stock
$336,205
Net cash provided by
financing activities
$136,205
(95.60%↑ Y/Y)
Canceled cashflow
$200,000
Net increase in cash
-$432,627
(-167.93%↓ Y/Y)
Canceled cashflow
$136,205
Inventory
-$81,172
(-142.68%↓ Y/Y)
Prepaid expenses
-$54,185
(-227.49%↓ Y/Y)
Lease cost, net of
repayments
$39,366
Accrued expenses
$5,761
(-68.87%↓ Y/Y)
Accounts payable
$3,441
(-59.08%↓ Y/Y)
Deferred tax asset
-$2,069
Operating expenses paid
with digital assets
$4
Repayment of related party
note payable
$200,000
Net cash provided by
(used in) operating...
-$541,874
(-188.35%↓ Y/Y)
Canceled cashflow
$185,998
Net cash used in
investing activities
-$26,958
Accounts receivable
$318,621
(9.97%↑ Y/Y)
Net income (loss)
-$185,753
(-121.00%↓ Y/Y)
Income tax payable
-$79,543
Deferred revenue
-$74,200
(-133.08%↓ Y/Y)
Income tax receivable
$34,992
Digital assets
-$8,519
Purchase of intangible
assets
$26,958
(-41.48%↓ Y/Y)
Back
Back
Cash Flow
BioScience Health Innovations, Inc. (BHIC)
BioScience Health Innovations, Inc. (BHIC)
source: myfinsight.com